홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
HUMA
#3068
Humacyte, Inc. Common Stock
1.1
2
-6.67%
부문:
베이스:
수익 통화:
일일 변동 비율
년간 변동
일일 변동
-6.67%
월간 변동
+7.69%
6달 변화
-28.66%
년간 변동율
-66.06%
이전 종가
1.2
0
Open
1.1
2
Bid
Ask
Low
1.1
2
High
1.1
2
양
61
마켓
주식
헬스케어
HUMA
Open full chart
Financials
Overview
성명
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
12.86 M
103 M
103.33 M
119.08 M
155.12 M
—
Valuation ratios
Enterprise value
—
529.28 M
68.25 M
263.7 M
738.41 M
1.54 B
Price to earnings ratio
—
-10.98
-17.58
-2.7
-4.01
-18.69
Price to sales ratio
—
222.91
138.94
—
149.58 K
—
Price to cash flow ratio
—
3.57
3.06
4.08
6.1
13.08
Price to book ratio
—
2.37
1.86
22.06
11.36
16.39
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
—
0.09
0.06
0.86
1.08
0.86
Return on equity %
—
0.22
0.1
8.18
2.82
14.46
Return on invested capital %
—
406.93
562.3
737.13
646.28
477.43
Gross margin %
—
100
100
—
100
—
Operating margin %
—
6 246.77
5 405.75
—
2.86 M
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
2 038.46
764.54
—
3.72 M
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
5.02
20.75
7.88
4.52
2.4
10.15
Inventory turnover
—
—
—
—
—
—
Asset turnover
—
0.01
0.01
0
0
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
0.1
0.1
0.3
0.46
1.53
Long term debt to total equity ratio
—
0.22
0.17
2.85
1.2
23.11
Per share metrics
Operating cash flow per share
—
2.03
0.69
0.71
0.83
0.76
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
5.64
1.47
0.78
0.38
1.22
Net current asset value per share
—
5.74
1.5
0.81
0.4
1.56
Tangible book value per share
—
3.06
1.13
0.13
0.44
0.77
Working capital per share
—
5.46
1.31
0.63
0.24
0.94
Book value per share
—
3.06
1.13
0.13
0.44
0.77
뉴스
Humacyte, Inc. (HUMA) Falls More Steeply Than Broader Market: What Investors Need to Know
BTIG, Humacyte에 ’매수’ 등급 재확인…미 국방부 자금 지원 소식에
BTIG reiterates Buy rating on Humacyte stock amid DoD funding news
휴마사이테, 혈관 복구 기술 국방부 자금 확보 후 주가 급등
Humacyte stock jumps after securing DoD funding for vascular repair tech
DoD, 2026년 예산에 생체공학 혈관 복구 기술 자금 배정
DoD allocates funds for bioengineered vascular repair tech in 2026 budget
Humacyte, Inc. (HUMA) Exceeds Market Returns: Some Facts to Consider
Humacyte 목표 주가, Benchmark, 10달러로 하향 조정
Benchmark lowers Humacyte stock price target to $10 on Israel filing plans
Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year?
Humacyte plans to seek approval for vessel product in Israel